The reform of imported drugs registration encourages the marketing of new drugs in China

作者/编者:Huang Jianwen
作者单位:金杜律师事务所
创作年代:2017
出处/来源:金杜律师事务所
学科分类:知识产权法学
所属机构:金杜律师事务所
文献语种:

摘要

On October 10 2017, the China Food and Drug Administration (“CFDA”) issued the Decisions Concerning the Adjustment of Imported Drug Registration (No. 35 Order by CFDA, “Decisions”). This implements the policy of encouraging new drug marketing following the earlier issuances of Opinions on Deepening the Reform of Evaluation and Approval System and Encouraging the Innovation of Drugs and Medical Devices by the General Office of the CPC Central Committee and the General Office of the State Council on October 8. This article will analyze the three major issues affected by the Decisions, including synchronized declarations of research & development for multi-regional clinical trials are permitted, the application for import marketing registration directly of drugs in MRCT and the removal of certain import drugs’ overseas marketing requirements.

关键词: Imported Drugs Registration; New Drugs; Multi-regional Clinical Trials

正文

备注

本文献PDF共计4页,免费分享。

为你推荐RECOMMEND

收藏
翻译服务
下 载

该文档为付费内容,请购买后阅读全文

翻译服务

The reform of imported drugs registration encourages the marketing of new drugs in China

我们提供文献翻译服务,请填写您的联系方式,方便我们与您取得联系

提交
客服热线:13801067850 座机:010-88578296

提交成功

我们会在3个工作日内与您取得联系,请保持手机联系方式畅通